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Human mesenchymal stem cells (MSCs)communicate with other cells in the human body and appear to “home” to areas of injury
inresponsetosignalsofcellulardamage, knownashomingsignals.Thisreviewofthestateofcurrentresearch onhoming ofMSCs
suggests that favorable cellular conditions and the in vivo environment facilitate and are required for the migration of MSCs to
the site of insult or injury in vivo. We review the current understanding of MSC migration and discuss strategies for enhancing
both the environmental and cellular conditions that give rise to eﬀective homing of MSCs. This may allow MSCs to quickly ﬁnd
and migrate to injured tissues, where they may best exert clinical beneﬁts resulting from improved homing and the presence of
increased numbers of MSCs.
1.Introduction
The promise of regeneration is what has sparked an inter-
national eﬀort to expand the ﬁeld of stem cell research.
In particular, the study of mesenchymal stem cells (MSCs)
and their eﬀects on cellular degenerative diseases is rapidly
increasing. The role of MSCs in the modulation of the
immune response, immune system activity, and the body’s
response to inﬂammation and disease has been widely stud-
iedformanyyears[1–5].Multiplestudieshavedemonstrated
that cultured MSCs have the ability to diﬀerentiate into
bone and cartilage [6, 7]a sw e l la so t h e rc e l lt y p e sa n d
tissues both in vitro and in vivo [2, 6, 8]. Among other
researchers, Ankrum and Karp demonstrated that MSCs
diﬀerentiate into osteocytes, adipocytes, neural cells, and
vascular endothelial cells [2].
Recent research, however, has shown that the environ-
ment plays a crucial role in limiting or expanding the
diﬀerentiation capacity of MSCs [9–13]. Lavasani et al. [13]
demonstrated that muscle stem cells from young mice con-
ferred signiﬁcant lifespan and healthspan extension in pro-
geroid mice, which have stem cells defective in proliferation
and multilineage diﬀerentiation. Furthermore, microen-
vironmental changes regulate the potential of MSCs to
diﬀerentiate into speciﬁc cell types [14–17], and this eﬀect
on diﬀerentiation seems to be characterized by a variety of
factors not yet well understood, such as the length of telom-
eres of cells in the microenvironment [10, 18]. While bone
marrow MSCs (BMMSCs) were shown to have a decreased
lifespan, rate of population doubling time [19], actual bone
formation as patient age increased [14], adipose tissue-
derived MSCs (AdMSCs) do not appear to undergo the
same senescence pattern as BMMSCs [10, 18]. Mirsaidi et al.
[18] demonstrated that murine AdMSCs derived from senile
osteoporotic SAMP6 mice showed maintenance of telomere
length, telomerase activity, and osteogenic diﬀerentiation. In
addition,Chenetal.[10]demonstratedthathumanAdMSCs
from elderly (mean age: 71.4 years) and young (mean age:
36.4 years) donors showed similar increases in proliferation
rate, osteogenic diﬀerentiation potential, and senescence
marker patterns, while BMMSCs from the same cohorts
showed reduced proliferation rate, decreased diﬀerentiation
potential, and increased senescence. Ultimately, however,
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reciprocal. Just as the microenvironmental eﬀects on MSCs
canconstricttheirresponsetoabodilyinsult,MSCscanacti-
vate or deactivate immune system within the environment
[1, 5]. MSCs are sometimes referred to as “balancers” due to
the extensive research linking the presence and activity of
in vivo MSCs and homeostasis [20].
The notion of balance is somewhat circuitous; MSCs
appear to both rely upon and cocreate a network that faci-
litates constant communication between normal and dam-
aged cells in the body [20]. MSCs are dispatched by what
might be metaphorically compared to a ﬁre alarm, through
a signaling system that has been extensively studied but
remains not fully understood. In particular, the factors that
trigger MSC responses and the tools required for MSCs
to respond in a positive way to a particular insult to the
body remain largely unknown [21–25]. To eﬀectively ﬁght
the ﬁres in our bodies, an adequate supply of MSCs with
high potential are needed to, metaphorically, act as ﬁreﬁght-
ers. Properly culture-expanded and engineered MSCs with
enhanced homing capability can ensure removal of the
damaged cells and increase the rate of regeneration when the
balance is disrupted in the body. Furthermore, strategies to
modulate the physiological barrier of blood vessels and the
lung, the inﬂammatory microenvironment of the body, and
the chemotactic signals from the damage site will enhance
MSC homing. A variety of strategies have been suggested
to enhance the homing of MSCs based on their well-known
characteristics.
In this paper, we will review the current understanding
of MSC migration and discuss strategies for enhancing their
traﬃcking to injured tissues to improve the clinical beneﬁts
of MSC transplantation.
2. Characterizationand Phenotype of MSCs
To explore the migration and homing of MSCs, ﬁrst it
is necessary to describe the diﬀerences among the types
of MSCs and to identify the taxonomy of MSCs and
the range of their environments and behaviors. MSCs
are deﬁned as multipotent cells with self-renewal capacity,
capable of diﬀerentiating into a variety of cells [26]. Since
the ﬁrst isolation of MSCs from the bone marrow by
Friedenstein and colleagues [27], MSCs have been derived
from multiple tissues [2]. Since diﬀerent methods have
been employed to culture MSCs from multiple tissues,
to assess their diﬀerentiation potential and to evaluate
their capacity for self renewal, it is critical to set accepted
criteria for deﬁning MSCs. Given the lack of universally
accepted criteria for deﬁning MSCs, the Mesenchymal and
Tissue Stem Cell Committee of the International Society
for Cellular Therapy proposed a set of standards to deﬁne
MSCs for both laboratory-based scientiﬁc investigations
and preclinical studies [28]. These are: (1) plastic adher-
ence ability; (2) lack of hematopoietic markers, such as
CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-
DR; (3) tripotential mesodermal diﬀerentiation potency
into osteoblasts, chondroblasts, and adipocytes. Along with
mesodermal diﬀerentiation capability, MSCs were shown
to diﬀerentiate into cells of the ectodermal lineage such
as neurons [29–31], keratocytes [32], and keratinocytes
[33], but also into cells of the endodermal lineage such as
hepatocytes [34, 35] and pancreatic β-cells [36]. Although
the diﬀerentiation capability of MSCs into cells of the
ectodermal and endodermal lineages has been demonstrated
in previous studies, MSC diﬀerentiation to these lineage cells
requires further investigation. Besides cellular diﬀerentia-
tion,throughaninteractionwithaseriesofsignalsfromlocal
tissue, engrafted MSCs can secrete diverse cytokines, pos-
sess trophic and immunomodulatory functions, and subse-
quently contribute to tissue repair and/or regeneration [2].
MSCs are found in various tissues and organs, including
fat, periosteum, synovial membrane, synovial ﬂuid, muscle,
dermis, deciduous teeth, pericytes, trabecular bone, infrap-
atellar fat pad, articular cartilage, umbilical cord and cord
blood [37, 38], and the placenta [39]. BMMSCs were ﬁrst
isolatedandusedindiseaseindications[40].Aspiratingbone
marrow from patients is an invasive procedure [41]a n d
yields only low numbers of cells(about 1–10 cellsper 1 × 105
cells or 0.0001–0.01% of all bone marrow nucleated cells),
requiring longer and more complex in vitro cellular expan-
sion procedures [42]. However, Ohgushi et al. [43]d e m o n -
strated that BMMSCs cultured from 3mL of aspirated bone
marrow obtained by noninvasive needle aspiration under
local anesthesia showed therapeutic eﬀects in treating osteo-
arthritis [43]. The therapeutic potential of BMMSCs was
inﬂuenced by donor age, showed declining diﬀerentiation
capacity, and reduced vitality in vitro with increasing donor
age [44] .A d i p o s et i s s u ei sa na t t r a c t i v es o u r c eo fM S C sf o r
stem cell therapy because it is easily obtainable in suﬃcient
quantities by a minimally invasive procedure [45, 46].
Furthermore, adipose tissue contains more MSCs than does
thebonemarrow(about100,000MSCspergramoffat)[47],
while diﬀerentiation and immunomodulatory potencies of
AdMSCs are equivalent to those of BMMSCs [46]. Of inter-
est, a comparative study on the diﬀerentiation capability
between BMMSCs and AdMSCs was performed using cells
from the same donor rat. Hayashi et al. clearly demonstrated
anexcellentosteogenicdiﬀerentiationcapabilityofBMMSCs
compared with AdMSCs derived from the same donor rat
[48].
3. Distribution of MSCs after Systemic Infusion
The distribution and migratory properties of systemically
injected MSCs is helpful in determining the metrics of hom-
ing eﬃciency. After intravenous delivery, MSCs are found
at low or very low frequencies in most target organs, as
shown by ﬂuorescent protein labeling [49–52], transduction
of MSCs with reporter genes [53, 54], detection of human
genes in animal recipients [55–58], sex-linked chromo-
some gene for sex mismatch [59, 60], histology [51, 61],
immunohistochemistry [53, 54, 56, 57], real-time PCR [49,
59], and ﬂuorescent in situ hybridization [59, 60]. For
instance, in baboons, by detecting transplanted cell-speciﬁc
DNA, Devine et al. [49] demonstrated a high number of
transplanted cells observed in gastrointestinal tissues and a
relatively high number of cells also observed in the kidney,
lung, liver, thymus, and skin. The levels of engraftment inStem Cells International 3
these tissues were estimated, ranging from 0.1% to 2.7%
of the administered cells. In noninjury models, by detect-
ing enhanced green ﬂuorescent protein (GFP)-transfected
murine MSC, Deak et al. [52] demonstrated that the most
frequently GFP-positive organs were the lungs, liver, kidney,
skin, and gut among investigated tissues 24h after MSC
transplantation. However, the aforementioned methods are
invasive and static, meaning the cells are not dynamically
tracked. To overcome these problems, non- or minimally-
invasive and eﬃcient real-time imaging techniques are
required. The development of noninvasive techniques such
as magnetic resonance imaging (MRI) on superparamag-
netic iron oxide (SPIO) nanoparticle-labeled MSCs [62–64],
combinedsingle-photonemissionCT(SPECT)/CTscanning
[65], and quantum dot tracking [66, 67] has enhanced our
ability to investigate MSC homing as well as the behavior
andorgan-speciﬁcaccumulationoftransplantedMSCs.MRI
cell tracking using SPIO is thought to be the lowest risk
alternative for monitoring stem cell activity in humans due
to the widely available data regarding the risk of MRI and the
factthatSPIOsareFoodandDrugAdministrationapproved.
Hsiaoetal.[62]reportedthatMSCsweresuccessfullylabeled
with Ferucarbotran, a clinically used ionic SPIO, without the
aid of a transfection agent, and did not aﬀect cell viability,
proliferation, mitochondrial membrane potential change,
reactive oxygen species production, or diﬀerentiation capac-
ity. Approximately 45.2% of labeled MSCs can be detected at
a single-level 3D gradient echo sequence and four repetitions
using 1.5T MRI. Reagan and Kaplan [64] reviewed the
details of MRI methods used to track cells and the potential
and challenges for each technique in clinical translation.
Using SPECT/CT imaging in an acute myocardial infarction
model, Kraitchman et al. [65] demonstrated that the initial
localization of BMMSCs was observed in the lung and the
cells moved to nontarget organs such as the liver, kidney,
and spleen within 24 to 48h after infusion. An increase
in MSCs found in the infarcted heart tissue was observed
with a simultaneous decrease in the initial concentration of
MSCs in the lung 24h after infusion, and MSCs persisted
until 7 days after injection. In addition, the labeling of
BMMSCs with bioconjugated quantum dots does not alter
the self-replication and diﬀerentiation potential of MSCs
into chondrogenic, osteogenic, and adipogenic cells [66],
and is very useful not only for tracking MSCs but also in
investigating the behavioral changes of cells when MSCs are
injected in combination with chemical compounds such as
drugs like heparin [67]. By imaging mice with acute liver
failure,Yukawaetal.[67]reportedthatwithin10minalmost
all transplanted AdMSCs accumulated in the lungs in the
absence of heparin treatment. However, when heparin was
used in combination with AdMSCs, the accumulation of
the transplanted stem cells was found not only in the lungs
but also in the liver, and the accumulation increased by
about 30% in the injured liver. Collectively, studies using
diﬀerent methods for tracking MSCs have shown an initial
concentration of MSCs in the lung after transfusion [52, 65,
67–69], after which most MSCs moved gradually to injured
sites [52, 65, 67, 69] or to the liver, spleen, kidney, and bone
marrow [68].
4. Migration and Homing Potential of MSCs to
Sites of Injury after Systemic Infusion
The ability to regenerate damaged tissues is a common cha-
racteristic of multicellular organisms. A cycle of apoptosis
and tissue regeneration exists in organisms, and stem cells
in and around damaged tissues play among the most critical
roles in wound healing and tissue regeneration [20]. It was
generally assumed that factors released upon tissue damage
or apoptosis mobilize and recruit stem and progenitor cells
to the damaged site, where they proliferate and diﬀeren-
tiate, eventually replacing the damaged tissues [22, 25].
However, a lack of data exists concerning the mechanisms
driving MSC traﬃcking after intravenous, intraarterial, or
local intra-tissue application compared with the relatively
well-characterized leukocyte homing cascade [70]. Recently,
Karp and Leng Teo [24] deﬁned MSC homing as the
“arrest of MSCs within the vasculature of the respective
tissue,” followed by transmigration across the endothelium.
Chemokines, cytokines, and growth factors released upon
injury provide migratory cues for systemically or locally
administered stem cells. The cues induce upregulation of
selectins and activation of integrins on the stem cell surface,
enabling cells to interact with the endothelium. Stem cells
subsequently adhere and transmigrate across the endothelial
layer into tissues. Regarding the homing capability of MSCs,
numerous studies have conﬁrmed that systemically infus-
ed MSCs can migrate to injured, inﬂamed tissues and
exert therapeutic eﬀects [21, 23]. BMMSCs, delivered intra-
venously to rats following myocardial infarction localize in
the infarct region and improve ventricular function, while
MSCs delivered intravenously to noninfarcted rats localize
to the bone marrow [71]. In addition, localized abdomen
irradiation has been shown to signiﬁcantly enhance MSC
homing speciﬁcally to radiation-injured tissues in mice [72].
Human AdMSCs infused by tail vein mobilized to cell-
damaged areas in an allergic rhinitis animal model [73].
Evidence conﬁrms the involvement of chemokines or
growth factors as migratory cues in MSC traﬃcking to the
injured region [24]. The interactions of stromal cell-derived
factor-1α (SDF-1α) and C-X-C chemokine receptor type 4
(CXCR4) were found to mediate the traﬃcking of trans-
planted BMMSCs in a rat model of left hypoglossal nerve
injury. Inﬂammatory cytokines, transforming growth factor
(TGF)-β1, interleukin (IL)-1β, and tumor necrosis factor
(TNF)-α upregulate the production of matrix metallopro-
teinases (MMPs) in MSCs, resulting in a strong stimulation
of chemotactic migration through the extracellular matrix,
while the chemokine SDF-1α exhibited minor eﬀects on
MMP/tissue inhibitor of metalloproteinase (TIMP) expres-
sion and cell invasion [74]. BMMSCs are mobilized by
chemokines that are present in the supernatants of primary
cultures of human pancreatic islets culture in vitro and in
vivo [75]. Human AdMSCs migrate in response to a variety
of growth factors and cytokines including platelet-derived
growth factor (PDGF)-AB, TGF-β1, TNF-α,a n dS D F - 1 α
[76]. Of interest, in a previous study, human AdMSCs pre-
stimulated with TNF-α showed enhanced migratory activity
compared to the nonpretreated control group [76]. These4 Stem Cells International
results indicate that enhancement of the homing capacity
of MSCs can be achieved by modulating the response of
MSCs to a variety of growth factors and cytokines, thereby
improving their therapeutic potential.
5. Homing Strategiesto Enhance Efﬁcacy and
Safety of MSC Therapy
Locally or systematically introduced MSCs have been used
for cellular therapy for a variety of indications. BMMSCs
have been used in a number of published interventions for
a range of therapeutic applications [77, 78]. Among other
applications, BMMSCs have been used to reduce clinical
symptoms of osteogenesis imperfecta [79]a n dt ot r e a tl a r g e
bone defects [80], in regenerative treatments to enhance
repair of pancreatic islets [81], and in infarcted myocardium
[82–84]. Furthermore, BMMSCs have been applied in a
variety of immunomodulatory treatments of autoimmune
diseases,includingCrohn’sdisease[85,86],multiplesclerosis
(MS) [87], and rheumatoid arthritis (RA) [88].
Like BMMSCs, AdMSCs have been demonstrated in
clinical trials to be safe and suitable for introduction into the
human body following culturing [89–91]. Local or systemic
administration of AdMSCs was reported to have therapeutic
eﬃcacy in treating myocardial infarction [92], liver injury
[93], hypoxia-ischemia-induced brain damage [94], allergic
rhinitis [73], and muscular dystrophy [95]. Furthermore, the
immune regulatory ability of AdMSCs has warranted their
therapeutic application to treat immune-related diseases
including graft versus host defense (GVHD) [96], rheumatic
disease [97], and thyroiditis [98]. Systemic infusion of AdM-
SCs before transplantation of haploidentical hematopoietic
stemcells(HSCs)controlslethalGVHDreactionofallogenic
HSCsinmice[96].HumanAdMSCsreduceddiseaseseverity
in experimental autoimmune thyroiditis via downregulation
of Th1 cytokines and improved Th1/Th2 balance [98].
In humans, systemic administration of autologous human
AdMSCs is a promising alternative to treat patients with
autoimmune diseases including autoimmune ear disease,
MS, polymyositis, atopic dermatitis, and RA [99]. In each
of these therapeutic applications, the ability of stem cells
to home to the site of injury was critical to their in vivo
eﬀects on the symptoms or underlying pathologies of these
diseases.
Homingmayprovideanimportantclinicalapplicationof
MSCs in the future as a cellular vehicle for anticancer thera-
p e u t i c si nt u m o r s[ 89]. Maestroni et al. [100] reported that
BMMSCs induced signiﬁcant reductions in size and metas-
tasis of lung cancer cells or melanoma cells in mice. Because
tumors release a range of cytokines and preferentially recruit
MSCs, stem cells may be used to deliver antitumor drugs in
a preclinical setting. Studeny et al. [101, 102] demonstrated
that BMMSCs transfected with IL-1β migrated to tumors
and exerted an anticancer eﬀect by secreting IL-1β. Khakoo
and his team [103] reported that a single injection of human
BMMSCs into the tail vein of immunocompromised mice
bearing Kaposi’s sarcoma suppressed tumor growth by more
than 50%, and two injections suppressed the growth even
further. Hakkarainen et al. [104]l o a d e dM S C sd e r i v e df r o m
bone marrow and adipose tissue with oncolytic adenovirus
and injected the stem cells into the tail vein of mice bearing
lung and breast cancer cells. The authors found that the stem
cells did not home to tumors but increased the therapeutic
eﬃcacy in lung and breast cancer cells compared to the con-
trol group injected with the virus alone. In 2007, Kucerova
et al. [105] subdermally and systemically injected AdMSCs
overexpressing a cancer cell cytotoxic prodrug, cytosine
deaminase (CD), into mice bearing HT-29 colon cancer.
Direct migration of CD-AdMSCs to the colon cancer cells
was observed in vitro, and a signiﬁcant inhibition of tumor
growth was observed by subcutaneously or intravenously
administered CD-AdMSCs in immunocompromised mice
treated with 5-ﬂuorocytosine. Qiao et al. [106]r e p o r t e d
that human MSCs signiﬁcantly inhibited the proliferation,
colony-forming ability, and oncogene expression growth in
malignant liver cancer cell lines, H7402 and Hep2, both in
vitro and in vivo through Wnt signaling pathway. There were
nocasesofrecurrenceduringthe100-dayobservationperiod
that followed. In 2009, Cousin et al. [107] demonstrated that
human AdMSCs strongly inhibit the proliferation of pan-
creatic ductal adenocarcinoma both in vitro and in vivo
through altering cell cycle progression, thereby inducing
tumor cell death. Canine adipose-derived stem cells loaded
with interferon-β in combination with an anticancer drug,
cisplatin, was shown to inhibit the growth of melanoma cells
in mice [108].
Although there may be a plateau between the number of
delivered cells and improvement of clinical outcome [54], a
higher number of infused MSCs are expected to give rise to a
higher number of engrafted MSCs and better functional out-
comes [109, 110]. Below, several factors that aﬀect the hom-
ing potential of MSCs will be discussed, including the quality
of MSCs per se, the ability of MSCs to respond to migratory
stimuli, the physiological barrier blocking MSC migration,
and the inﬂammatory microenvironment of the body. A
variety of strategies are suggested to enhance the homing of
MSCs given their known homing characteristics.
5.1. Cultivating MSCs with Enhanced Migratory Ability by
Optimizing Cell Culture Conditions. Highly active MSCs or
progenitors are naturally attracted to signals that come from
sites of injury [25]. Thus, the culture process of MSCs
should maintain the characteristics of the donor/recipient’s
MSCs, that is, their homology. It has been demonstrated that
cell culture conditions including the passage number, con-
ﬂuency of the passaged cells, and oxygen concentration have
a signiﬁcant impact on the expression of cell surface recept-
ors of MSCs responding to migratory signals. The passage
number of MSCs aﬀects homing as MSCs have been shown
to gain or lose certain surface receptors during culture.
Freshly isolated MSCs display enhanced homing ability com-
pared to their culture-expanded counterparts [111]. Hom-
ingreceptorsCXCR4,achemotacticreceptorforSDF-1αthat
is upregulated in the bone marrow and in ischemic tissues,
is usually absent on the surface of culture-expanded MSCs
[8, 112–114]. However, treatment of MSCs with a cocktail of
cytokines in culture has been shown to induce high surface
expression of CXCR4 [115].Stem Cells International 5
The conﬂuency of cultured MSCs prior to therapeutic
infusion also aﬀects migration potential. Lee et al. [116]
investigated the diﬀerences between low-passage and low-
density cultures versus MSCs from expanding, near-con-
ﬂuent cultures. Six surface markers were found preferentially
expressed on early passage MSCs in low conﬂuency cultures:
podocalyxin-like protein PODXL, CD49f, CD49d, cMet,
CXCR4, and CX3CR1. Sorting PODXLhi/CD49fhi cells with
speciﬁc antibodies resulted in selection of early MSC pro-
g e n i t o r st h a tw e r el e s sp r o n et op r o d u c el e t h a lp u l m o n a r y
emboli and increased homing to the heart in a murine
myocardial infarction model. De Becker et al. [117]d e m o n -
strated that high culture conﬂuence inhibited transendothe-
lial migration in MSCs by increasing the production of a
natural matrix MMP inhibitor, TIMP-3.
The oxygen level in cell culture conditions also inﬂuences
cell homing [118, 119]. Exposure of MSCs to hypoxic con-
ditions increased CXCR4 and CX3 chemokine receptor 1
(CX3CR1) expression, which leads to increased migration
in response to SDF-1α. Grafting experiments using xeno-
typic chick embryo showed that cultured MSCs under
hypoxicconditionsengraftedmoreeﬃcientlycomparedwith
cells from normoxic cultures [119]. Rosov´ a et al. [120]
demonstrated that MSCs cultured in hypoxia activated the
Akt signaling pathway while maintaining their viability
and cell cycle rates. Hypoxic preconditioning also induced
expressionofcMet,themajorreceptorforhepatocytegrowth
factor, and enhanced cMet signaling. Migration rates are
also increased in hypoxia, and hypoxic preconditioning
increasedMSCmigration inMatrigelbyupregulatingMMPs
[121].
Although a number of strategies have been discussed
to improve culture conditions, the most critical aspect for
clinical application of MSCs is the safety of cultured cells.
Ex vivo expansion of MSCs for long-term culture alters the
characteristicsofMSCs,includingtheirproliferativecapacity
[122], diﬀerentiation potential [123], and trophic activity
[124]. We previously provided substantial guidelines for
evaluating the safety of cultured MSCs by conducting in
vitroand in vivo assays under good laboratory practices [91].
Theseassaysincludesterility,immunophenotyping,diﬀeren-
tiation potential, genetic stability test, in vivo toxicology, and
tumorigenicity tests in laboratory animals and in vivo safety
tests in the spinal cord of patients receiving 400 × 106 stem
cells intravenously.
5.2. Enhancing the Ability of MSCs to Respond to Migratory
Stimuli. To respond to migratory signals released in sites
of injury, MSCs must express surface receptors capable of
sensing those signals. Various studies to modify MSCs or to
enhance expression of surface markers have been explored
to enhance MSC migration. A key player in MSC migration
is the CXCR4-SDF-1α axis [24]. Many studies have focused
on ways to enhance the functional expression of CXCR4
in MSCs to migrate toward chemotactic SDF-1α secreted
at injury sites. Modiﬁcation of CXCR4 expression with
retroviral overexpression, mRNA transfection of CXCR4-
GFP [125], and cytokine pretreatment especially TNF-α
resulted in increased migration toward SDF-1α in vitro [76,
126]. Maijenburg et al. [127] investigated gene expression
proﬁles involved in the process of MSC migration and
found 12 diﬀerentially expressed genes in migratory MSCs
compared to nonmigrating MSCs. Among them, the nuclear
receptors Nur77 and Nurr1 showed the highest expression
in migratory MSCs. The expression of these receptors
rapidlyincreasedunderstimulationwithSDF-1αandPDGF-
BB. Genetically engineered MSCs overexpressing Nur77 or
Nurr1 showed enhanced migration toward SDF-1α and
decreased cell proportion in S-phase cell cycle. Monocyte
chemoattractant (MCP)-1 is typically expressed at sites
of inﬂammation and can thus represent a model homing
chemokine [128]. GFP-labeled MSCs expressing the MCP-
1 receptor, chemokine receptor (CCR) 2, on the cell surface
were systemically infused into transgenic mice expressing
MCP-1speciﬁcallyinthemyocardium.Ahigherfrequencyof
GFP-positive cells (20 cells/microscopic ﬁeld) was observed
in the myocardium of the transgenic mice compared to
the hearts of control mice 7 and 14 days later. In another
study, the upregulation of the α4 subunit of the VLA-4-
integrin on MSCs using an adenovirus vector resulted in
successful dimerization with β1-integrin and increased the
homing ability of MSCs to the bone marrow by more than
10 fold as compared to nontransduced MSCs [129]. Since
human MSCs do not express E-selectin ligands, Sackstein
and colleagues enzymatically modiﬁed the native CD44 gly-
coform on MSCs into hematopoietic cell E-selectin/L-
selectin ligand, resulting in increased MSC migration to the
bone marrow [117].
5.3. Modulating Physiological Barriers Blocking MSC Migra-
tion into the Site of Injury. Noninvasive administration of
stem cells is more convenient and compassionate than
invasive methods for cell therapy, particularly when the
patient suﬀers from degenerative conditions or has an auto-
immune indication. Blood vessels are the primary route
through which MSCs circulate in the body. The vessels need
to be clear of debris and broken capillaries must be ﬁxed in
order for the cells to travel to the appropriate sites in the
body. Thus, the body’s revascularization capacity must be
adequate. If the injured area is in need of further therapy,
more infused cells may be required. In these cases, the blood
vessels must be clot-free, allowing cells to reach the area
of injury during subsequent infusions. Furthermore, MSCs
must pass through physical lung barriers and transmigrate
into the tissue of injury. To solve the problems induced by
microvessels and the lung, Yukawa et al. [67]p r o p o s e da
combination of MSCs and heparin. When only MSCs were
injected systemically in the mice, almost all transplanted
MSCs were accumulated in the lungs. However, when the
mice were treated with heparin, accumulations decreased in
the lung and increased in the acute injured livers of these
mice.
When cultured MSCs are infused into the body, what
kinds of conditions can impair the ability of cells to reach
their ﬁnallocation at theinjury site? Modulating the harmful
environment can improve the migration of MSCs into target
tissues. Sites of tissue damage undergo chronic or acute
immune responses, and MSCs migrating to these sites will6 Stem Cells International
encounter various immune cells in the local environment.
Thus, MSC cellular regeneration can be inﬂuenced by
immune cells in the damaged sites [130]. Liu et al. [130]p r e -
sented ﬁndings that provide novel insight into how the host
immune systems communicate via interferon (IFN)-γ and
TNF-α with transplanted MSCs during bone formation and
repair. The authors demonstrated that systemic infusion of
regulatory T cells or local administration of aspirin markedly
enhanced the survival of BMMSCs and improved bone
regeneration of transplanted MSCs through suppression of
IFN-γ and TNF-α in damaged bone sites.
5.4. Stimulating the Target Site to Recruit MSC Mobilization.
In the acute phase of injury, factors released from damaged
tissues recruit blood cells and MSCs to repair the injured
site. In this regard, substantial evidence indicates that infus-
ed MSCs have higher engraftment eﬃciencies within sites
of inﬂammation or injury. Franc ¸ois et al. [58]a p p l i e d
total body irradiation (TBI) or TBI in combination with
additional local irradiation into the abdominal area or hind
leg of mice. The authors found that the engraftment level of
systemically infused MSCs was higher in mice subjected to
TBI compared to nonirradiated mice. Cho et al. [73] also
demonstrated that inﬂammatory stimuli of allergic rhinitis
induced the homing of intravenously administered hAdM-
SCs to cell-damaged areas. Taken together, the evidences
indicate that signals are required to recruit MSCs with high
eﬃciency, which is critical for improving the clinical beneﬁts
of MSCs. However, in a variety of clinical indications, MSCs
are administered to damaged tissues at the subchronic or
chronic phases of injury, in which the migratory signals for
MSCs may be minimal or absent. Thus, exogenous stimuli
are necessary to recruit infused MSCs into subchronic or
chronic phases of injury sites for high eﬃcacy of MSC
therapy.
In this regard, electric stimuli can be a good candidate
directing MSCs migration to injured sites. Evidence demon-
strates that electrical stimulation (ES) induces the migration
and stimulation of adult cells, including stem cells, and
improves the clinical beneﬁt. Electrical current applied to
wounded tissue activates and migrates ﬁbroblasts, which
play a critical role in wound healing [131, 132]. Gardner
et al. [133] performed a meta-analysis on the eﬀect of ES
on chronic wound healing in human patients and reported
that ES increased the rate of chronic wound healing to 144%
that of the control in 24 studies. In an animal model of
spinal cord injury, application of an electrical ﬁeld (EF)
resulted in functional improvement [134]. On the basis of
the eﬀects of EFs on functional improvement in animal
models of spinal cord injury (SCI), Shapiro et al. [135]
applied weak EF stimulation in human SCI in a phase I trial
and reported considerable clinical beneﬁt. Perry et al. [136]
applied degenerate electrical waveforms in the treatment of
skin scarring in 30 patients with over 140 scars with long-
term pain and itching. After monitoring for 6 months, the
authors reported that ES treatment resulted in a clinically
and statistically signiﬁcant reduction of symptoms and scar
scores. Zhao et al. [137] demonstrated that physiological EF
of ∼25mV/mm in vitro directed the migration of cultured
BMMSCs mainly to the anode. Increasing the EFs enhanced
the migration of the MSC and peaked the response at
300mV/mL at a rate of 42 ± 1μm/h, around double the
migration rate of the control (no EF). Of importance, EF did
not inﬂuence cell senescence, phenotype, or the osteogenic
potential of MSCs, regardless of passage number within the
range tested (P3–P10). Recently, it has been demonstrated
the combination of MSC transplantation with ES can be a
therapeutic tool to improve the eﬃcacy of transplantation.
Wu et al. [138] demonstrated that implanted spike wave
ES improved the survival of BMMSCs after transplantation
comparedtoBMMSCstransplantationorEStreatmentalone
using an in vivo rat model of spinal cord injury. Fur-
thermore, analysis of functional parameters demonstrated
improved functional recovery in the BMMSCs + ES groups.
Taken together, it can be hypothesized that applying ES
around injured sites can direct migration of exogenously
infused MSCs and enhance the migration of MSCs dur-
ing the healing process. This hypothesis requires further
veriﬁcation.
6. Conclusions
The eﬀorts of researchers to establish the safety of MSC
infusion and their eﬀects in vivo have led to the application
of MSCs for the treatment of various tissue degenera-
tive indications in humans [99]. Thus far, most of the
procedures involve local administration or direct injec-
tion [http://www.clinicaltrials.gov/]. However, for condi-
tions such as Alzheimer’s, Parkinson’s, liver disease, renal
failure, and autoimmune diseases, the delivery of MSCs by
systemic infusion can be minimally invasive and convenient.
To make a systemic infusion eﬃcacious, more MSCs are
needed by comparison to local delivery. MSCs can be
expanded via in vitro culture, which unfortunately presents
high costs. Thus, further research is required to understand
the factors aﬀecting the eﬃciency of MSC migration and to
determine strategies to remove harmful factors and improve
homing of MSCs to the area of injury. New strategies could
mean smaller quantities of MSCs necessary for infusion,
thereby attaining the intended therapeutic goal with greatest
eﬃciency and eﬃcacy. To achieve this goal, cell migration
and tracking studies must be conducted in various in
vivo environments along with in vitro laboratory studies.
Through these studies, optimized culture conditions can be
established to cultivate MSCs with enhanced homing ability
and expressing the appropriate homing receptor. This is also
essential to improve vascular conditions, so that introduced
cells can easily migrate to damaged sites. In addition, it is
critical to determine exogenous stimuli such as ES to recruit
infused MSCs into the subchronic or chronic injury sites.
Ultimately, the future of stem cell therapy depends, as does
so much of science in general, on understanding the nature
of responses to illness. Just as bees are naturally attracted to
ﬂowers and men are attracted to women, the philosophy of
research of MSC migration and homing should focus on the
nature of life.Stem Cells International 7
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